Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a potent, long-acting inhibitor of angiotensin converting enzyme (ACE), with an IC₅₀ of 4.7 nM under standard assay conditions (pH 8.3, 25°C) (Tieku & Hooper 1992). Its specificity enables targeted suppression of the renin-angiotensin system, leading to reduced angiotensin II and aldosterone levels. The compound is water-soluble (≥2.46 mg/mL with warming/sonication), but insoluble in ethanol. APExBIO supplies Lisinopril dihydrate (SKU: B3290) with ≥98% purity, confirmed by MS and NMR (APExBIO product page). It is a key reagent in cardiovascular and nephropathy research, supporting high reproducibility in experimental models (related review).

Biological Rationale

Lisinopril dihydrate is the dihydrate salt form of lisinopril, a lysine analogue of MK 421. It is classified as a long-acting angiotensin converting enzyme (ACE) inhibitor. ACE catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Inhibition of ACE is a validated strategy to lower blood pressure and reduce cardiac and renal workload (Tieku & Hooper 1992). The renin-angiotensin system (RAS) is central to blood pressure regulation and fluid-electrolyte balance. By blocking ACE, lisinopril dihydrate disrupts this pathway, reducing vasoconstriction and aldosterone-mediated sodium retention. The compound is widely used in research models of hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy (mechanistic review).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate binds to and inhibits the active site of ACE (EC 3.4.15.1), a zinc-dependent dipeptidyl carboxypeptidase. The inhibition is competitive and reversible. In vitro, it achieves 50% inhibition (IC₅₀) at 4.7 nM when assayed with Hip-His-Leu substrate in 50 mM HEPES, pH 8.3, at 25°C (Tieku & Hooper 1992). Inhibition of ACE blocks conversion of angiotensin I to angiotensin II, resulting in decreased plasma levels of angiotensin II, suppression of aldosterone secretion, and compensatory elevation in plasma renin activity. This sequence leads to vasodilation, reduced vascular resistance, and lowered blood pressure.

Lisinopril dihydrate does not significantly inhibit other zinc metallopeptidases, such as aminopeptidase A (AP-A; EC 3.4.11.2), aminopeptidase N (AP-N; EC 3.4.11.7), or aminopeptidase W (AP-W; EC 3.4.11.16), at pharmacologically relevant concentrations (Tieku & Hooper 1992). This high selectivity supports its use in mechanistic studies targeting the renin-angiotensin system without confounding off-target effects.

Evidence & Benchmarks

• Lisinopril dihydrate inhibits ACE (IC₅₀ = 4.7 nM, 25°C, pH 8.3), demonstrating nanomolar potency in standard enzymatic assays (Tieku & Hooper 1992).
• It does not significantly inhibit AP-A, AP-N, or AP-W, indicating high selectivity for ACE over related zinc aminopeptidases (Tieku & Hooper 1992).
• The molecular weight of Lisinopril dihydrate is 441.52 g/mol; its chemical formula is C₂₁H₃₅N₃O₇ (APExBIO product page).
• The compound is soluble in water at ≥2.46 mg/mL with warming and ultrasound treatment, but insoluble in ethanol (APExBIO).
• Lisinopril dihydrate is routinely used in preclinical models of hypertension, heart failure, myocardial infarction, and diabetic nephropathy (site article).

Applications, Limits & Misconceptions

Lisinopril dihydrate is extensively utilized in:

• Hypertension research: Modeling essential and renovascular hypertension via RAS modulation.
• Heart failure models: Assessing the impact of ACE inhibition on cardiac remodeling and function.
• Acute myocardial infarction studies: Investigating infarct size reduction and ventricular protection mechanisms.
• Diabetic nephropathy models: Examining renoprotection and proteinuria reduction.

This article extends prior summaries such as 'Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hyper...' by providing updated quantitative benchmarks and clarifying selectivity details. For advanced applications and troubleshooting, 'Lisinopril Dihydrate: Molecular Insights for Next-Gen Car...' discusses structure-activity relationships, while this article focuses on verified usage parameters and pitfalls.

Common Pitfalls or Misconceptions

• Non-selectivity assumption: Lisinopril dihydrate does not inhibit AP-A, AP-N, or AP-W at standard research concentrations; off-target effects are minimal (Tieku & Hooper 1992).
• Solubility confusion: The compound is only water-soluble with warming/ultrasonication; it is insoluble in ethanol and most organic solvents (APExBIO).
• Stability concerns: Stock solutions are not stable for long-term storage; it is recommended to prepare fresh aliquots and store the solid desiccated at room temperature.
• Incorrect pathway assignment: Lisinopril dihydrate acts exclusively on the renin-angiotensin system and does not directly inhibit other vasoregulatory pathways.

Workflow Integration & Parameters

Formulation: Dissolve Lisinopril dihydrate in sterile water at concentrations up to 2.46 mg/mL using gentle warming and ultrasonic bath. Avoid ethanol or DMSO as solvents due to insolubility. Filter-sterilize if required for cell culture or in vivo use.

Storage: Store the solid compound desiccated at room temperature. Do not store aqueous solutions long-term; prepare fresh before each experiment. Shipping is on blue ice for small molecule preservation (APExBIO).

Quality: APExBIO's B3290 kit provides ≥98% purity, batch-certified by mass spectrometry and NMR. For documentation and ordering, refer to the Lisinopril dihydrate product page.

Experimental Design: For in vitro inhibition, typical working concentrations range from 1–100 nM. For in vivo preclinical studies, dosing must be based on model species, route, and endpoint, referencing peer-reviewed protocols.

For troubleshooting and advanced workflow guidance, 'Lisinopril Dihydrate: Precision ACE Inhibitor for Hyperte...' provides detailed application strategies, while this article centers on validated core parameters and product specifications.

Conclusion & Outlook

Lisinopril dihydrate is a validated, highly selective ACE inhibitor with robust physicochemical and pharmacological credentials. Its predictable mechanism and high purity, as supplied by APExBIO, support reproducible research in hypertension, cardiac, and renal models. Future directions include refinement of dosing paradigms and integration with multi-omics workflows. For detailed product information and ordering, visit the Lisinopril dihydrate product page.